Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
|Articles|August 31, 2006
Merck KGaA To Build Biopharmaceutical Plant in Germany
Author(s)Patricia Van Arnum
Merck KGaA (Darmstadt, Germany) plans to invest 190 million euros ($245 million) to build a biopharmaceutical plant in Darmstadt, Germany. Production is expected to begin in 2010.
Advertisement
Darmstadt, Germany (Aug. 29)-Merck KGaA (
The new plant will mainly produce the monoclonal antibody "Erbitux" (cetuximab). Erbitux is currently manufactured for Merck KGaA by Boehringer Ingelheim (Ingelheim, Germany,
www.boehringer-ingelheim.com
) and ImClone Systems, Inc. (New York, NY,
www.imclone.com
). Merck KGaA acquired the rights to develop and market Erbitux outside the United States and Canada from ImClone Systems and shares marketing rights for Erbiutx with ImClone. Bristol-Myers Squibb Company (New York, NY,
www.bms.com
) and ImClone have rights for the product in the United States and Canada.
Advertisement
Related to this article
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
Advertisement
Advertisement